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Critical role of CD11b+ macrophages and VEGF in
inflammatory lymphangiogenesis, antigen clearance, and
inflammation resolution
Abstract
Using a bacterial pathogen-induced acute inflammation model in the skin, we defined the roles of local
lymphatic vessels and draining lymph nodes (DLNs) in antigen clearance and inflammation resolution.
At the peak day of inflammation, robust expansion of lymphatic vessels and profound infiltration of
CD11b+/Gr-1+ macrophages into the inflamed skin and DLN were observed. Moreover, lymph flow
and inflammatory cell migration from the inflamed skin to DLNs were enhanced. Concomitantly, the
expression of lymphangiogenic growth factors such as vascular endothelial growth factor C (VEGF-C),
VEGF-D, and VEGF-A were significantly up-regulated in the inflamed skin, DLNs, and particularly in
enriched CD11b+ macrophages from the DLNs. Depletion of macrophages, or blockade of VEGF-C/D
or VEGF-A, largely attenuated these phenomena, and produced notably delayed antigen clearance and
inflammation resolution. Conversely, keratin 14 (K14)-VEGF-C transgenic mice, which have dense and
enlarged lymphatic vessels in the skin dermis, exhibited accelerated migration of inflammatory cells
from the inflamed skin to the DLNs and faster antigen clearance and inflammation resolution. Taken
together, these results indicate that VEGF-C, -D, and -A derived from the CD11b+/Gr-1+ macrophages
and local inflamed tissues play a critical role in promoting antigen clearance and inflammation
resolution.
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VASCULAR BIOLOGY
Critical role of CD11b macrophages and VEGF in inflammatory
lymphangiogenesis, antigen clearance, and inflammation resolution
Raghu P. Kataru,1 Keehoon Jung,1 Cholsoon Jang,1 Hanseul Yang,1 Reto A. Schwendener,2 Jung Eun Baik,3
Seung Hyun Han,3,4 Kari Alitalo,5 and Gou Young Koh1
1National Research Laboratory of Vascular Biology and Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST),
Daejeon, Korea; 2Laboratory of Liposome Research, Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland; 3Department of Oral
Microbiology and Immunology, Dental Research Institute, School and BK21 Program of Dentistry, Seoul National University, Seoul, Korea; 4International Vaccine
Institute, Seoul, Korea; and 5The Molecular/Cancer Biology Laboratory, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
Using a bacterial pathogen–induced acute
inflammation model in the skin, we defined
the roles of local lymphatic vessels and
draining lymph nodes (DLNs) in antigen
clearance and inflammation resolution. At
the peak day of inflammation, robust expan-
sion of lymphatic vessels and profound
infiltration of CD11b/Gr-1 macrophages
into the inflamed skin and DLN were ob-
served. Moreover, lymph flow and inflamma-
tory cell migration from the inflamed skin to
DLNs were enhanced. Concomitantly, the
expression of lymphangiogenic growth fac-
tors such as vascular endothelial growth
factor C (VEGF-C), VEGF-D, and VEGF-A
were significantly up-regulated in the in-
flamed skin, DLNs, and particularly in en-
riched CD11bmacrophages from the DLNs.
Depletion of macrophages, or blockade of
VEGF-C/D or VEGF-A, largely attenuated
these phenomena, and produced notably
delayed antigen clearance and inflamma-
tion resolution. Conversely, keratin 14 (K14)–
VEGF-C transgenic mice, which have dense
and enlarged lymphatic vessels in the skin
dermis, exhibited accelerated migration of
inflammatory cells from the inflamed skin to
the DLNs and faster antigen clearance and
inflammation resolution. Taken together,
these results indicate that VEGF-C, -D, and
-A derived from the CD11b/Gr-1 macro-
phages and local inflamed tissues play a
critical role in promoting antigen clearance
and inflammation resolution. (Blood. 2009;
113:5650-5659)
Introduction
Peripheral tissues, such as skin and mucosa, are exposed to external
environments and are constantly challenged by antigens. Some
antigens, such as pathogen molecules derived from bacteria and
viruses, evoke inflammatory responses in these tissues through a
consecutive set of processes: activation of residential macrophages
and mast cells leading to secretion bioactive amines, cytokines,
chemokines, and lipid mediators; recruitment of leukocytes includ-
ing neutrophils, monocytes, and T lymphocytes from circulation;
activation of macrophages and dendritic cells (DCs) to engulf dead
leukocytes, pathogens, and other inflammatory debris; and drain-
age of these cells into draining lymph nodes (DLNs) via local
lymphatic vessels.1-3 Throughout these processes, residential and
recruited monocyte-derived macrophages are critical for evoking
and resolving the acute inflammation caused by pathogen entry.1-5
The pathophysiologic, molecular, and cellular mechanisms govern-
ing initiation and promotion of inflammatory processes have been
extensively characterized; however, it is yet to be clarified how
acute inflammation resolves, rather than leads to, chronic inflamma-
tion. Particularly, the roles of local lymphatic vessels and DLNs in
antigen clearance and inflammation resolution are poorly
understood.
During inflammation, macrophages actively participate in induc-
ing the formation of new lymphatic vessels.6-13 In adult animals,
new lymphatic vessels are formed mainly through lymphangiogen-
esis, which is a sequence of processes that include sprouting,
migration, proliferation, and tubule formation by preexisting
lymphatic endothelial cells (LECs).14-16 Additional LECs may also
be derived through transdifferentiation or incorporation of circulat-
ing bone marrow–derived cells and some macrophages.9,11 The
discovery of specific lymphangiogenic growth factors (VEGF-C
and VEGF-D), receptors (VEGF receptor-3 [VEGFR3]), a transcrip-
tion factor (Prox-1), and markers (lymphatic vessel endothelial
hyaluronan receptor-1 [LYVE-1], podoplanin) for LECs has led to
a renewed interest in the roles of lymphatic vessels and lymphangio-
genesis in tissue fluid homeostasis, tumor metastasis, wound
healing, antigen presentation, and digested lipid absorption.14-19
Among the roles of lymphatic vessels and lymphangiogenesis, the
functional importance of lymphatic vessels in inflammation was
initially observed a long time ago.20 Lymph nodes, in concert with
the lymphatic vessels, play a pivotal role in initiating adaptive
immune responses.21 Notably, local tissue inflammation causes
DLNs to undergo a transient but profound remodeling, with
volume expansion, lymphoid hyperplasia, and markedly increased
lymphatic vessel densities.22,23 Lymphatic vessels in DLNs act as
essential conduits for antigen-presenting cells such as epidermal
Langerhans cells and dermal DCs to T lymphocytes.21 Up-
regulated induction of inflammatory adhesion molecules in the
lymphatic vessels within inflamed DLNs enhances DC mobiliza-
tion to the T lymphocytes.24-26 The main mediators and factors
governing inflammation-induced lymphangiogenesis (IIL) are yet
to be defined. Intriguingly, our pilot experiment revealed that in
bacterial pathogen–induced inflamed skin and DLNs, CD11b
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macrophages were profoundly infiltrated around expanded lym-
phatic vessels. Based on this observation, we have speculated that
macrophages, including CD11b macrophages, play a pivotal role
in the expansion of lymphatic vessels in the inflamed skin and
DLNs by secreting lymphangiogenic growth factors. Moreover, we
have sought to determine whether macrophage-induced lymphangio-
genesis may be actively involved in antigen clearance, in addition
to initiating the adaptive immune response.
In this study, we investigated the role of IIL in antigen clearance
and inflammation resolution. To this end, we generated an inflam-
mation model by the introduction of representative etiologic agents
capable of inducing septic shock. These agents are lipopolysaccha-
ride (LPS) from Gram-negative bacteria and a mixture of lipotei-
choic acid (LTA) from Gram-positive bacteria plus muramyl
dipeptide (MDP),27,28 which were injected into the dorsal side of
ear dermis of mice. At the peak day of acute inflammation, we
analyzed changes in lymphatic vessels, macrophage infiltration,
lymph flow, inflammatory cell migration, antigen clearance, and
inflammation resolution from the inflamed skin and DLNs in
normal adult mice and in skin-specific VEGF-C–overexpressing
transgenic mice.29 To determine the role of macrophages and
lymphangiogenic growth factors in these processes, specific agents
that block macrophage and lymphangiogenic growth factors were
applied. Our results indicate that macrophages, including CD11b/
Gr-1 macrophages, play a critical role in antigen clearance and
inflammation resolution, and VEGF-C, -D, and -A derived from the
macrophages, local inflamed tissue, and DLNs contribute to
accelerate antigen clearance and inflammation resolution.
Methods
Mice
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). GFP mice (C57BL/6J genetic background) were a gift from Dr
Masaru Okabe (Osaka University, Osaka, Japan).30 K14-VEGF-C trans-
genic mice (FVB/N genetic background) were generated and maintained as
previously described,29 and transferred to KAIST. Mice were bred in our
pathogen-free animal facility, and male mice aged 7 to 8 weeks were used.
Animal care and experimental procedures were performed under approval
from the Animal Care Committee of KAIST.
Ear skin inflammation model
LPS (from Escherichia coli 0111:B4) and MDP were purchased from
Sigma-Aldrich (St Louis, MO). Highly purified and structurally intact LTA
was prepared from Staphylococcus aureus (ATCC, Manassas, VA) as
previous described.28 Mice were anesthetized by intramuscular injection of
a combination of anesthetics (80 mg/kg ketamine and 12 mg/kg xylazine),
then a single intradermal injection of LPS (10 g in 10 L PBS) or
LTA MDP (10:1 ratio, 10 g LTA  1 g MDP in 10 L PBS)27 was
given into the dorsal side of the ear using a 31-gauge syringe.
Depletion of macrophages and blockades of VEGF ligands
For systemic depletion of macrophages, mice were given an intravenous
injection of clodronate liposome (CDL, 25 mg/kg)31 through the tail vein at
1 day before and after the intradermal injection of LPS or LTA. To block
VEGF-C/D, mice were treated with a single intravenous injection of 109 pfu
Ad-sVEGFR332 at 12 hours before the intradermal injection of LPS or LTA.
To block VEGF-A, mice were given a subcutaneous injection of VEGF-
Trap (25 mg/kg)33,34 or anti–VEGF-A blocking antibody (4 mg/kg; R&D
Systems, Minneapolis, MN) under the back skin at 1 day before and after
the intradermal injection of LPS or LTA.
Histologic and morphometric analyses
Mice were anesthetized by intramuscular injection of anesthetics, as
described in “Ear skin inflammation model,” at the indicated times after the
intradermal injection of LPS or LTA. The histologic and morphologic
analyses in the inflamed ear and DLNs were performed as described in
Document S1 (available on the Blood website; see the Supplemental
Materials link at the top of the online article).
Flow cytometric analysis of CD11b macrophages from ear
skin and DLNs
After anesthesia, the ears and DLNs were harvested and dissected into small
pieces by a microscissor, and the pieces were incubated with 2 mL Hank
balanced salt solution (Sigma-Aldrich) containing 0.2% collagenase type-II
(Worthington, Lakewood, NJ) for 1 hour at 37°C. Flow cytometric analysis
of CD11b macrophages from ear skin and DLNs was performed as
described in Document S1.
Enrichment of CD11b cells from DLNs by MACS
CD11b macrophages in the DLN were enriched using anti–mouse CD11b
antibody-coupled MicroBeads (Miltenyi Biotec, Auburn, CA) and a
magnetic cell sorter (magnetic-activated cell sorting [MACS]; Miltenyi
Biotec) according to the manufacturer’s instructions as described in
Document S1.
Assessment of inflammation in the ear skin
Ear thickness was measured by a Flat Anvil type caliper (cat no. 7301;
Mitutoyo, Kawasaki, Japan). Swelling and erythema were graded by
severities as described in Tables S1,S2.
RT-PCR
The semiquantitative and quantitative real-time reverse-transcription–
polymerase chain reaction (RT-PCR) of total RNA isolated from ear
skin, whole DLNs, and MACS-enriched CD11b cells from the DLNs
was performed with appropriate primers (Table S3) as described in
Document S1.
Monitoring lymph flow
Monitoring lymph flow was performed using 2 intravital imaging methods
as described in Document S1.
Assay for inflammatory cell migration from the inflammation
site to DLNs
GFP mice were intraperitoneally injected with 1 mL 3.0% thioglycolate
(Sigma-Aldrich) in saline, and inflammatory cells were collected 3 days
later by peritoneal washing with ice-cold DMEM culture medium. Approxi-
mately, 106 GFP inflammatory cells in 10 L PBS were adaptively
transferred by injection at the inflamed site of the ear. Twelve hours
later, DLNs were collected and sectioned for immunohistology, and a
cell suspension was made by collagenase digestion for the flow
cytometric analysis.
Monitoring antigen clearance
The monitoring antigen clearance was performed as described in
Document S1.
Statistics
Values presented are means plus or minus standard deviation (SD).
Significant differences between means were determined by Student t test or
analysis of variance (ANOVA) followed by the Student-Newman-Keuls
test. Statistical significance was set at a P value less than .05.
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Results
Depletion of macrophages markedly reduces
lymphangiogenesis in the inflamed skin and DLNs, and delays
inflammation resolution
Acute skin inflammation induced by intradermal injection of LPS
(10 g in 10 L PBS; hereafter referred to as LPS) or LTA (10:1
ratio, 10 g LTA plus 1 g MDP in 10 L PBS; hereafter referred
to as LTA) evokes robust lymphangiogenesis and marked recruit-
ment of CD11b/Gr-1 macrophages in the inflamed skin and
DLNs (Figures S1-S4). These results led us to explore the
involvement of macrophages, including CD11b/Gr-1 macro-
phages, in lymphangiogenesis in the inflamed skin and DLNs by
depletion of whole macrophages by intraperitoneal treatment with
clodronate liposome (CDL).31 The CDL treatment, but not control
liposome (CL) treatment, efficiently depletes macrophages, includ-
ing CD11b/Gr-1 macrophages, in all organs, including inflamed
skin and DLNs (Figures 1A and 2A, and data not shown) by
inducing apoptosis of macrophages.31 In this situation, the LPS- or
LTA-induced increased lymphatic vessel densities and sprouting
and infiltration of CD11b/Gr-1 macrophages were largely attenu-
ated, not only in the inflamed skin but also in the DLNs (Figures
1,2). However, unexpectedly, the skin thickness was increased to a
greater extent in LPS  CDL and LTA  CDL than in LPS  CL
and LTA  CL (Figure 1A,B). In comparison, the inflamed skin
and DLNs treated with LPS  CL or LTA  CL showed no
significant differences in any parameters examined compared with
the skin and DLNs treated with only LPS or LTA. In addition, the
inflamed skin and DLNs treated with the CL or CDL showed no
significant differences compared with the skin and DLNs treated
with PBS (Figures 1,2). To determine the role of macrophages in
inflammation resolution, we further examined LPS- or LTA-
induced inflammatory reactions in the ear skin after treatment with
CL or CDL. Compared with the inflamed skin treated with
LPS  CL and LTA  CL, the inflamed skin treated with
LPS  CDL and LTA  CDL exhibited exaggerated inflammatory
reactions including severe swelling, erythema formation, and
corresponding histologic changes (Figure S5). Local depletion of
macrophages by a localized injection of CDL, but not CL, into the
inflamed skin produced similar findings (data not shown). These
data suggest that LPS- or LTA-induced recruitment of macro-
phages, including CD11b/Gr-1 macrophages, plays a critical
role not only in lymphangiogenesis in the inflamed skin and DLNs,
but also in inflammation resolution in the inflamed skin.
Depletion of macrophages markedly reduces lymphatic flow
and mobilization of inflammatory cells from the inflamed ear
skin to the DLNs
To elucidate the underlying mechanism of how macrophages play a role
in inflammation resolution, we first monitored lymph flow from the
inflamed ear skin to DLNs. As a monitoring system, we obtained
simultaneous vital images for 30 minutes using an in vivo imaging
system (IVIS) imaging system and a fluorescence stereomicroscope to
track the movement of a lymphatic tracking fluorescent dye, fluorescein
isothiocyanate (FITC)–dextran, at the injection site on day 3 after the
LPS or LTAinjection. Fluorescence intensities in the DLNs were similar
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Figure 1. Depletion of macrophages including CD11b/Gr-1 macrophages markedly reduces LPS- or LTA-induced lymphangiogenesis in the skin. CDL (25 mg/kg,
CD) was given intravenously to deplete macrophages at 1 day before and after the intradermal injection of LPS (LPS  CDL) or LTA (LTA  CDL). For controls, CL (25 mg/kg)
was given in the same manner (LPS  CL, LTA  CL). As an alternative control, PBS (P), CL, or CDL-only was given in the same manner. At day 3 after the injection of LPS or
LTA, the inflamed ears were excised and sectioned for histologic analysis or digested for flow cytometry. (A) Tissue sections were coimmunostained for LYVE-1, CD31, or
CD11b and merged. ™ indicates lymphatic sprouts. Scale bars represent 50 m. (B) Quantification analyses of lymphatic (LV) and blood vessel (BV) densities (%), number of
lymphatic sprouts, thickness of the ear skins, and number of CD11b/Gr-1 cells in the gated area (No/GA) are shown. All bars represent mean  SD from 4 to 5 mice.
*P  .05 versus CL; #P  .05 versus LPS  CL or LTA  CL. (C) Flow cytometric analysis of CD11b/Gr-1 macrophages in the ear skins.
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in PBS, PBSCL, and PBSCDL, whereas they were slightly but
significantly higher in LPSCL and LTACL (Figure 3A-C),
indicating greater lymphatic flow during LPS- and LTA-induced inflam-
mation. However, fluorescence intensities in the DLNs were lower in
LPSCDL and LTACDL than in LPSCL, LTACL, and PBS
(Figure 3A-C), indicating that lymphatic flows were decreased by
depletion of macrophages, even during LPS- and LTA-induced inflam-
mation. Second, we determined the mobilization rate of inflammatory
cells from the inflamed ear skin to DLNs by the intradermal injection of
GFP inflammatory cells ( 106 cells). Twelve hours after the injection
of green fluorescent protein–positive (GFP) inflammatory cells, the
mobilized inflammatory cells were localized mainly in the pericapsular
region of DLNs and rarely detectable in the paracortical region of DLNs
in PBS (Figure 3D). Compared with PBS, the number of the mobilized
inflammatory cells substantially increased both in the pericapsular
region ( 3.3-fold and  2.8-fold by LPSCL and LTACL,
respectively) and paracortical region ( 6.1-fold and  5.5-fold by
LPSCL and LTACL, respectively; Figure 3D,E). However,
compared with LPSCL and LTACL, the numbers of the mobi-
lized inflammatory cells were markedly lower in both the pericapsular
region ( 63% and  62% by LPSCDL and LTACDL, respec-
tively) and the paracortical regions ( 90% and 85% by LPSCDL
and LTACDL, respectively; Figure 3D,E). Flow cytometric analyses
on the total DLNs exhibited similar findings (Figure 3F). These data
suggest that macrophages play a substantial role in increases of lymph
flow and inflammatory cell mobilization from the inflammatory site to
the DLNs for antigen clearance and inflammatory resolution.
Role of paracrine factors associated with CD11b/Gr-1
macrophages in LPS- and LTA-induced dermal and DLN
lymphangiogenesis
To investigate the source and expression of lymphangiogenic
factors that drive LPS- or LTA-induced lymphangiogenesis, we
performed a series of reverse-transcription–polymerase chain reac-
tion (RT-PCR) assays in the skins and their DLNs with and without
macrophage depletion by CDL treatment, and in the enriched
CD11bmacrophages from DLNs. Compared with PBS, LPS CL
and LTA  CL increased VEGF-A164 (2.3- and 2.2-fold, respec-
tively), VEGF-A120 (2.6- and 1.9-fold, respectively), VEGF-C (2.1-
and 1.9-fold, respectively), and VEGF-D (1.5- and 1.4-fold,
respectively) in the ear skins (Figure S6A,C). Compared with
PBS, LPS  CL and LTA  CL increased VEGF-A164 (2.4- and
2.3-fold, respectively), VEGF-A120 (3.1- and 3.2-fold, respec-
tively), VEGF-C (2.6- and 2.5-fold), respectively, and VEGF-D
(1.3- and 1.3-fold, respectively) in the DLNs (Figure S6A,C).
CDL treatment markedly reduced LPS  CL- and LTA  CL-
induced increases in expression of VEGF ligands in the ear skin
and DLNs, and the relative levels were similar to those of PBS.
In CD11b macrophages enriched by magnetic-activated cell
sorting (MACS), LPS and LTA increased VEGF-A164 (4.7- and
4.2-fold, respectively), VEGF-A120 (3.2- and 3.0-fold, respec-
tively), VEGF-C (4.8- and 3.4-fold, respectively), and VEGF-D
(3.6- and 3.1-fold, respectively), compared with PBS (Figure
S6B,D). Consistently, quantitative real-time RT-PCR analyses
revealed that LPS and LTA increased VEGF-A, VEGF-C, and
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Figure 2. Depletion of macrophages markedly reduces LPS- or LTA-induced lymphangiogenesis in the DLNs. CDL (25 mg/kg, CD) was given intravenously to deplete
macrophages at 1 day before and after the intradermal injection of LPS (LPS  CDL) or LTA (LTA  CDL). As a control, CL (25 mg/kg) was given in the same manner
(LPS  CL, LTA  CL). As alternative controls, PBS (P), CL, or CDL-only was given in the same manner. At day 3 after the injection of LPS or LTA, the DLNs were sampled and
sectioned for histologic analysis or digested for flow cytometry. (A) Tissue sections were coimmunostained for LYVE-1, CD31, or CD11b and merged. ™ indicates lymphatic
sprouts. Scale bars represent 50 m. Quantification of lymphatic (LV) and blood vessel (BV) densities (%; B), number of lymphatic sprouts (C), and number of CD11b/Gr-1
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VEGF-D mRNA levels, whereas they did not change the
placental growth factor (PlGF) mRNA level in the skin, DLNs,
and enriched CD11 macrophages (Figure S7). Thus, macro-
phages, including CD11b macrophages, could be the main
mediators or sources of lymphangiogenic VEGF ligands in the
skin and DLNs during acute IIL.
Blockade of VEGF-C/D or VEGF-A reduces the LPS- and
LTA-induced dermal and DLN lymphangiogenesis, lymph flow,
inflammatory cell migration, and inflammation resolution
The pacarine role of macrophages as a source of VEGFs led us to
explore the role of VEGF ligands on LPS- or LTA-driven lymphangio-
genesis, lymph flow, inflammatory cell migration, and inflammation
resolution. To block VEGF-C and VEGF-D (VEGF-C/D), an
adenovirus encoding the soluble extracellular domain of VEGFR-3
(Ad-sVEGFR3) was used.32 Compared with the control, which was
treated with 109 pfu adenovirus encoding -galactosidase (Ad-gal),
treatment with 109 pfu Ad-sVEGFR3 markedly attenuated the
LPA- and LTA-increased lymphatic density ( 47% and  48%,
respectively, in the skin and 50% and 52%, respectively, in the
DLNs), lymph flow ( 44% and  30%, respectively), and
inflammatory cell migration to DLNs ( 59% and 58%, respec-
tively, in the pericapsular region and  78% and  75%, respec-
tively, in the paracortical region), and delayed inflammation
resolution (Figures 4,S8). The mice treated with the Ad-gal
showed no significant differences from the mice treated with PBS.
Compared with the controls, which were treated with dimeric-Fc
protein, mice receiving a blockade of VEGF-A with either VEGF-
Trap33,34 or anti–VEGF-A antibody also had significant attenuation
of the LPA- and LTA-increased lymphatic density in the skin and
DLNs, increased lymph flow and inflammatory cell migration from
the inflamed skin to DLNs (pericapsular and paracortical regions),
and delayed inflammation resolution (Figures 5,S9,S10). The mice
treated with the dimeric-Fc protein showed no significant differ-
ences from the mice treated with PBS. In addition, flow cytometric
analysis of the DLNs revealed that infiltration of CD11b/Gr-1
macrophages to the DLNs was markedly decreased by blockade of
VEGF-C/D or VEGF-A (Figure S11). These results indicate that
VEGF-C, -D, and -A derived from inflamed skin and DLNs make a
major contribution to the induction of dermal and DLN lymphangio-
genesis by LPS and LTA, as well as to the enhancement of lymph
flow and inflammatory cell migration, and to the resolution of
inflammation.
Blockade of VEGF-C/D or VEGF-A delays antigen clearance
To ascertain whether VEGF-C, -D, and -A are involved in antigen
clearance through local lymphatic vessels and DLNs, a single
intradermal injection of FITC-LPS (10 g/ear in 10 L PBS) into
the ear skin was performed in the mice treated with the Ads-
VEGFR3, Ad-gal, VEGF-Trap, and dimeric-Fc, and the clearance
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of FITC-LPS was monitored. Compared with treatment with
Ad-gal, treatment with Ad-sVEGFR3 attenuated the disappear-
ance of FITC-LPS from the ear ( 19.8% at day 1 and 11.1% at
day 3; Figure 6A,C). Compared with treatment with dimeric-Fc
protein, treatment with VEGF-Trap attenuated FITC-LPS disappear-
ance from the ear ( 18.9% at day 1 and  7.5% at day 3), and
treatment with anti–VEGF-A antibody also attenuated FITC-LPS
disappearance from the ear ( 25.2% at day 1 and 4.4% at day 3;
Figures 6B,D, S12). Histologic analyses revealed that more
FITC-LPS remained in the injected ear skin of mice treated with
Ad-sVEGFR3, VEGF-Trap, or anti–VEGF-A antibody compared
with the mice treated with Ad-gal or dimeric-Fc (Figures 6E,
S12), confirming that blocking VEGF-C/D or VEGF-A delays
antigen clearance from the inflamed skin.
K14-VEGF-C transgenic mice display enhanced inflammatory
cell migration, antigen clearance, and inflammation resolution
Compared with wild-type littermates, K14-VEGF-C transgenic
mice displayed profoundly denser and larger lymphatic vessel
networks in the ear skin and DLNs (Figure 7A). Moreover, vital
fluorescence lymphangiography by injection of FITC-dextran
revealed an immediate and diffuse distribution of the FITC-dextran
from the injection site in the transgenic mice, compared with
limited and selective distribution of the FITC-dextran from the
injection site in normal littermates (Figure 7B). In the LPS-induced
inflamed skin, no differences were seen in the rate of lymphatic
drainage to the DLNs between the normal littermates and the
transgenic mice (Figure 7C,D). However, inflammatory cell migra-
tion into the DLNs was higher ( 7.8-fold) in the K14-VEGF-C
transgenic mice than in the normal littermates (Figure 7E,F).
Furthermore, the inflammatory responses to LPS, including swell-
ing and erythema, were significantly less in the transgenic mice
than in the normal littermates (Figure 7G,H), suggesting that
K14-VEGF-C transgenic mice have faster antigen clearance in the
skin. In fact, the disappearance of FITC-LPS from the ear was
significantly faster over time in the transgenic mice than in the
normal littermates (Figure 7I,J), further indicating faster antigen
clearance in the skin. To determine the role of macrophages in
lymphatic function in the K14-VEGF-C mice, lymph flow and
inflammatory cell migration were measured after treatment with
CL or CDL. Depletion of macrophages by CDL did not affect
lymph flow or inflammatory cell migration from the skin to DLNs
in the K14-VEGF-C mice (Figure S13A-D). Furthermore, deple-
tion of macrophages by CDL did not significantly exaggerate or
alleviate the LPS-induced inflammatory reactions, including severe
swelling and erythema formation (Figure S13E,F), indicating that
the profoundly denser and larger lymphatic vessel networks in the
ear skin and DLNs are sufficient to resolve inflammation and can
compensate for the role of macrophage-induced lymphangiogen-
esis in the inflamed skin.
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were sampled and sectioned for histology. Tissue sections were
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the inflamed ear skins (B) and DLNs (C) are quantified and
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cells ( 106 cells) were injected intradermally into the inflamed
skin. Twelve hours later, the DLNs were sectioned and immuno-
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Discussion
As part of the innate immune response during skin inflammation,
locally generated interstitial fluid containing activated immune
cells is drained unidirectionally into the DLNs via afferent
lymphatic vessels. The cellular and molecular mechanisms of DC
migration from inflamed skin to DLNs with respect to antigen
presentation have been well characterized.21-26 However, little is
known about the underlying cellular and molecular mechanisms for
clearance of pathogen molecules and the resolution of inflamma-
tion. In this study, we found that VEGF ligands secreted from
infiltrated macrophages, including CD11b/Gr-1 macrophages,
could be major mediators for pathogen clearance and inflammation
resolution through profound expansion of lymphatic vessels,
enhanced lymph flow, and mobilization of inflammatory cells from
the inflamed skin to the DLNs (Figure S14).
Macrophages play diverse roles in IIL.6-13 For example, CD11b
macrophages are actively involved in IIL in the cornea,10 and
VEGF-A stimulates IIL mainly via macrophage recruitment.6
Accordingly, depletion of macrophages abrogates this IIL.10 More-
over, normal wound healing requires macrophage-induced lym-
phangiogenesis.12,13 In a diabetic mouse model, administration of
macrophages promotes wound healing with enhanced lymphangio-
genesis,13 demonstrating the critical role of macrophages in IIL in
inflamed tissues. Our recent study in an ovarian cancer model
indicated that VEGF ligands derived from CD11b macrophages
induce profound but dysfunctional lymphangiogenesis in inflamma-
tory carcinogenesis.34 The present results show that acute inflamma-
tion induced by intradermal administration of virulence factors,
LPS and LTA, results in the abundant recruitment of CD11b/
Gr-1 macrophages, and these macrophages appear to induce a
temporary but profound lymphangiogenesis in the inflamed skin as
well as in the DLNs. Furthermore, the subsequent experiments
demonstrated that the CD11b/Gr-1 macrophages were mainly
F4/80 cells. These cells could have substantial phagocytic activity
because they were depleted by CDL, and F4/80 macrophages are
known to have a relatively high phagocytic activity.31,35 Because of
the phagocytic activity of these cells, they could actively partici-
pate in clearing dead leukocytes, pathogens, and cellular debris by
phagocytosis. Then these cells are transmigrated into the lumen of
local lymphatic vessels and finally drained into the DLNs.36 These
phagocytic macrophages are also known to be the main cell type
for secreting major cytokines, chemokines,1-5 and lymphangio-
genic growth factor.6-13 Indeed, upon phagocytosis of the apoptotic
bodies, macrophages secrete abundant VEGF-A, which promotes
endothelial cell growth.37 Our RT-PCR analyses revealed that
activated macrophages, including CD11b macrophages, are the
main producers of lymphangiogenic VEGF ligands in the inflamed
skin and DLNs during acute IIL. Furthermore, depletion of
macrophages largely attenuated IIL, indicating that macrophages
could be the major source of lymphangiogenic growth factors.
Thus macrophages, including CD11b/Gr-1/F4/80 macro-
phages, help themselves by laying the groundwork for their own
transportation to the DLN by secreting lymphangiogenic growth
factors (Figure S14).
Our results also show that profound increases of lymphatic
vessel density in the inflamed skin and DLNs result from active
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proliferation and sprouting of LECs. The proliferation and sprout-
ing of these cells are essential processes of lymphangiogenesis.14-16
The increased lymphatic vessel densities obviously increase the
surface area of the initial, collecting, and conduit lymphatic
vessels, and these vessels would facilitate entry and transport of
interstitial fluid and immune cells from the inflamed skin to the
conducting lymphatic vessels and the DLNs. Johnson et al showed
that the expression of the key leukocyte adhesion molecules,
intercellular adhesion molecule, and vascular cell adhesion mole-
cule, are up-regulated in LECs in inflamed skin, and these adhesion
molecules facilitate DC transmigration.38 Furthermore, Baluk et al
elegantly described the preferential entry of MHC-II DCs and
macrophages and CD45 leukocytes into the proximal half of
initial lymphatic vessels having “buttonlike junctions” in tracheal
mucosa during LPS-induced acute inflammation.39 Likewise, acti-
vated macrophages, including CD11b/Gr-1/F4/80 macro-
phages, could actively transmigrate to inflamed lymphatic vessels
by virtue of these up-regulated adhesion molecules, preferentially
through the proximal half of the initial lymphatic vessels. The
robust expansion of CD11b/Gr-1 macrophages observed in the
DLNs during acute skin inflammation implies recruitment of these
cells from the outside to the DLNs. Previous studies21,40-42 indicate
that recruitment of circulating monocyte-driven macrophages to
the DLNs during skin inflammation is mediated through high
endothelial venules (HEVs) by “remote control” of chemokines
including “macrophage chemoattractant protein-1” and “monokine
induced by gamma interferon” secreted from the inflamed skin
tissues. However, our compelling evidence favors a model in which
draining lymphatic vessels, rather than HEVs, are responsible for
the monocyte-driven macrophage recruitment to the DLNs during
acute inflammation. The evidence in favor of this model is (1) our
immunohistologic analyses revealing that robust increases of
CD11b macrophages are localized mainly around subcapsular
afferent lymphatic vessels, which are directly connected to periph-
eral tissues, and (2) the adaptively transferred inflammatory cells
are also localized mainly around subcapsular afferent lymphatic
vessels, with only a few localized in the HEV-rich regions of the
DLNs during the inflammation. Thus, the draining lymphatic
vessels that lead from the inflamed tissue to the DLNs are the main
routes for monocyte-driven macrophage recruitment to the DLNs
during acute inflammation.
Recently, lymphangiogenesis in the DLNs has emerged as a
significant factor in several pathophysiologic conditions. During
inflammation, B cell–driven DLN lymphangiogenesis enhances
DC mobilization,25 whereas tumor-induced DLN lymphangiogen-
esis enhances lymph flow and metastasis.43,44 These intriguing
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was visualized by a fluorescence stereomicroscope. Bottom
panels show higher magnifications. (C,D) At day 3 after the
injection of LPS, 3 L FITC-conjugated dextran was intradermally
injected into the inflamed skin. Fluorescence intensities were
determined in DLNs at 30 minutes after the injection using IVIS,
quantified, and presented as relative radiance (photon/sec per
cm2/steradian). (E,F) At day 3 after intradermal injection of LPS,
the GFP inflammatory cells ( 106 cells) were injected intrader-
mally into the inflamed skin. Twelve hours later, the DLNs were
sectioned and immunostained for LYVE-1. Scale bars represent
50 m. The GFP inflammatory cells in the DLNs were quantified
and presented as AU. (G,H) At day 6 after intradermal injection of
LPS, ears were photographed, and the severities of erythema and
swelling were scored. All bars represent mean  SD from 4 to
5 mice. *P  .05 versus wild type. (I,J) At days 0, 1, and 3 after the
injection of FITC-LPS, the remaining FITC-LPS was quantified
using IVIS and presented as relative radiance (photons/sec per
cm2/steradian). All dots represent mean  SD from 4 to 5 mice.
*P  .05 versus wild type; #P  .05 versus LPS in wild type.
Day 0
Day 1
Day 3
Ad-βgal         Ad-sVEGFR3     Fc                 VEGF-Trap    
F
IT
C
-
L
P
S
L
Y
V
E
-1
R
ad
ia
nc
e 
0
2
4
6
8
10
Ad-βgal           Ad-sVEGFR3     Fc                 VEGF-Trap     
0            1            3
Day after injection 
R
ad
ia
nc
e 
0
2
4
6
8
10
Day after injection 
0            1            3
Ad-sVEGFR3     
Ad-βgal
*
*
VEGF-Trap     
Fc *
*
A B
C D
E
Figure 6. Blockade of VEGF-C/D or VEGF-A delays FITC-LPS from the inflamma-
tion site to DLNs in the inflamed skin. AdsVEGFR-3 (R3) or Ad-gal (109 pfu) was
injected 12 hours before the intradermal injection of FITC-LPS into ear skin.
VEGF-Trap (25 mg/kg) or dimeric-Fc (Fc, 25 mg/kg) was given 1 day before and after
FITC-LPS into ear skin. (A-D) At days 0, 1, and 3 after the injection of FITC-LPS, the
remaining FITC-LPS was quantified with IVIS and presented as relative radiance
(photons/sec per cm2/steradian). All dots represent mean  SD from 4 to 5 mice.
*P  .05 versus Ad-gal or Fc. (E) At day 3 after the intradermal injection of
FITC-LPS, the ears were sectioned and immunostained for LYVE-1, and merged.
Scale bars represent 50 m. Four independent experiments show similar results.
INFLAMMATORY LYMPHANGIOGENESIS 5657BLOOD, 28 MAY 2009  VOLUME 113, NUMBER 22
 For personal use only. at UNIVERSITAETSSPITAL on June 3, 2009. www.bloodjournal.orgFrom 
reports led us to examine whether inflammation-induced DLN
lymphangiogenesis promotes inflammatory cell mobilization and
lymph flow, and subsequently enhances antigen clearance and
inflammation resolution. Indeed, our findings exhibited that DLN
lymphangiogenesis is closely linked to accelerated mobilization of
inflammatory cells and to a lesser extent, enhanced lymph flow,
from inflamed tissue to DLNs. IIL at the inflamed tissue could be an
additional factor in accelerating inflammatory cell mobilization and
lymph flow. Interestingly, Halin et al45 found that DLN lymphangio-
genesis during chronic inflammation is due to VEGF-A secreted
from the inflamed tissue, but not from the DLNs. However, our
results show a clear correlation between abundant macrophage
infiltration, up-regulated expression of VEGF-C, -D, and -A, and
increased lymphatic densities within the DLNs. Moreover, the
enriched CD11b macrophages from the DLNs displayed mark-
edly up-regulated expression of VEGF-C, -D, and -A. Furthermore,
depletion of macrophages including CD11b/Gr-1, and blockade
of VEGF-C/D or VEGF-A, largely attenuated DLN lymphangiogen-
esis. These data indicate that the lymphangiogenic growth factors
secreted from robustly infiltrated macrophages in the DLNs could
be the major driving force for DLN lymphangiogenesis. Therefore,
we propose that ILL in DLNs could be caused not only by VEGF
ligands from inflamed tissue, but also by VEGF ligands secreted
from CD11b/Gr-1 macrophages within DLNs in acute
inflammation.
The most intriguing and novel finding in this study is that
inflammation-induced up-regulation of VEGF-C, -D, and -A from
the macrophages and local tissues plays an active role in antigen
clearance and inflammation resolution by promoting IIL and
lymphatic function. Accordingly, depletion of macrophages or
blocking of VEGF-C/D or -A strikingly reduced inflammatory cell
migration, lymph flow, antigen clearance, and inflammation resolu-
tion with attenuated DLN lymphangiogenesis. Thus, these compo-
nents largely contribute to regulate inflammatory cell migration
and lymph flow directly and indirectly with the expansion of
lymphatic surface area through local and DLN lymphangiogenesis.
(Figure S14). Accordingly, the K14-VEGF-C transgenic mice with
abundant lymphatic vessels in skin and DLNs displayed higher
inflammatory cell migration, and faster antigen clearance and
inflammation resolution than the wild-type mice. In fact, VEGF-C
is known not only to augment lymphatic growth, but also to
maintain or enhance lymphatic functions including lymph drainage
and flow from the interstitial compartment to the lymphatic lumen
and DLNs,46 and VEGF-A is one of the most potent factors that
promotes permeability from the blood vascular lumen to the
interstitial compartment.47 Thus, because VEGF-C, -D, and -A may
control and contribute to homeostasis between lymph drainage and
flow and blood vascular permeability, disturbances in this homeosta-
sis could be involved in delayed antigen clearance and inflamma-
tion resolution in the inflamed skin tissue. However, it should be
noted that VEGF-Trap treatment attenuates the ability of transgenic
VEGF-A to induce chronic inflammation in skin, corneal inflamma-
tion, and the release of inflammatory cytokines induced by
polymicrobial sepsis.6,48,49 Therefore, the blockade of VEGF-A
with VEGF-Trap can reduce or promote inflammation, depending
on the type and location of the inflammation.
In conclusion, our findings shed light on an additional role of
macrophages during acute inflammation. The lymphangiogenic
growth factors secreted from infiltrated macrophages in inflamed
tissue and DLNs appear to be critical in lymphatic vessel expan-
sion, antigen clearance, and inflammation resolution through
enhancement of lymphangiogenesis, lymph flow, and mobilization
of inflammatory cells from inflamed tissue to the DLNs. A subset of
CD11b/Gr-1/F4/80 macrophages and the lymphangiogenic
growth factors VEGF-C, -D, and -A could be the key components
in promoting antigen clearance and inflammation resolution during
bacterial pathogen–induced acute inflammation. Disruptions in
these orchestrated cellular and molecular actions may disrupt early
inflammation resolution, leading to uncontrolled chronic
inflammation.
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